StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report released on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a report on Wednesday, August 7th.
Read Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, sell-side analysts predict that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Read More
- Five stocks we like better than Minerva Neurosciences
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- Following Congress Stock Trades
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Canadian Penny Stocks: Can They Make You Rich?
- MarketBeat Week in Review – 8/26 – 8/30
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.